Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kilts to oversee Gillette/P&G integration

This article was originally published in The Tan Sheet

Executive Summary

Gillette CEO James Kilts is stepping down as head of the blades and razors business effective July 1, P&G reports May 24. However, because "there is still a lot of work to do" regarding the Gillette integration, Kilts will continue with the company as vice chairman of P&G's board of directors until Oct. 1, a P&G spokesperson said. "Last year we planned the integration and the deal closed Oct. 1, so we're only about six months into the integration," he said. "There's still much more work ahead and [Kilts] will focus exclusively on that." P&G acquired Gillette Oral Care last year in a $57 bil. transaction (1"The Tan Sheet" Oct. 10, 2005, p. 13). Kilts will retire upon the Oct. 1 culmination of his duties, the firm noted; until then, he will continue reporting to President and CEO A.G. Lafley. The exec will be replaced by current President-Global Duracell & Braun Mark Leckie, who will assume his new position as group president-Gillette global business in July. Leckie will take on Kilts' day-to-day responsibilities, according to the firm...

You may also be interested in...



P&G Eyes Expanded Gillette Skin Care And Hair Care Offerings

Procter & Gamble will focus on growing Gillette's brand equity and product offerings in the midterm, P&G CFO Clayt Daley told analysts during an Oct. 3 conference call. P&G's $57 bil. acquisition of Gillette closed Oct. 1, one day after receiving FTC approval

Keeping Track: US FDA's Rejection Of First RMAT BLA Blemishes Otherwise Positive Week Of Non-Oncology News

The latest non-oncology drug development news and highlights from our US FDA Performance Tracker.

FDA Commissioner Nominee Hahn Advances To Full Senate, Despite Some Dems’ Reservations

Stephen Hahn, the Trump administration’s nominee to lead the US FDA, has been approved by the Senate Health, Education, Labor and Pensions (HELP) Committee, with some “no votes” from Democratic senators in leadership positions, and is expected to be considered by the full Senate this week.

Topics

UsernamePublicRestriction

Register

PS099412

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel